Immunai Inc., a New York-based biotechnology company specializing in artificial intelligence, has formed a multi-year collaboration with global pharmaceutical giant AstraZeneca. The partnership aims to leverage Immunai’s proprietary AI model, the IDE, to enhance clinical decision-making and improve the success rates of drug development programs.
 
Under the terms of the agreement, AstraZeneca will provide Immunai with $18 million for the initial phase of the collaboration. The companies will collaborate on various aspects of clinical research, including dose selection, elucidating mechanisms of action, analyzing patient responses, and identifying potential biomarkers. By applying Immunai’s AI technology to understand the human immune system at a single-cell level, the partners hope to gain valuable insights that can accelerate drug development and improve patient outcomes.
 
AstraZeneca has the option to extend the collaboration beyond the initial phase, potentially expanding its scope and duration. This partnership marks a significant step forward in utilizing AI to revolutionize the pharmaceutical industry and advance the development of innovative new therapies.
 
“This collaboration is a natural progression of our successful work in advancing drug development in the fields of oncology and immunology,” said Noam Solomon, Ph.D., CEO of Immunai. “Bringing a drug to market is incredibly challenging, time consuming and expensive. Through this collaboration with AstraZeneca, we’re excited to leverage our AI-based engine the IDE™ to help make this process more efficient in bringing potential new therapies to patients.”
 
“Artificial Intelligence is transforming cancer drug discovery and clinical development. We are very pleased to collaborate with Immunai to leverage their innovative platform to enhance our data-driven R&D strategy and glean potential new insights into mechanisms of action of immunotherapies,” said Iker Huerga, Chief Data Scientist, Oncology R&D, AstraZeneca.